Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of 9MW1911 in healthy subjects
NCT05170243Phase 1Completed
- Sponsor
- Mabwell
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD) comparing 9MW1911 Injection with 9MW1911 Injection Placebo (2 arms). Primary endpoint: Adverse Event (including serious adverse event). Started Jan 2022; status: completed.
02
Drugs
9MW1911
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05170243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170243.